Biogen's Slow Growth

Motley Fool - USA
... The big news for Biogen and partner Elan (Nasdaq: ELN) this quarter was the return to the US market of its multiple sclerosis drug, Tysabri. ...
See all stories on this topic

Biogen Idec and Elan Announce Availability of TYSABRI(R) for the ...
Finanzen.net - Germany
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc(NYSE: ELN) today announced the commercial availability of TYSABRI(R)(natalizumab) for the treatment of ...

Elan's Tysabri back on US shelves
RTE.ie - Ireland
Pharmaceutical company Elan and its partner Biogen have announced that their multiple sclerosis treatment Tysabri is now available again in the US. ...

Tysabri returns to market in US, Europe
Washington Post - United States
DUBLIN (Reuters) - Irish drug maker Elan (ELN.I) said on Monday its multiple sclerosis treatment Tysabri had returned to the market in the United States and ...

Elan/Biogen Idec: Tysabri back on the shelves
Pharmaceutical Business Review - USA
By Chantal Moore. Elan and Biogen Idec have successfully re-launched Tysabri in the US and introduced it to several European markets. ...
See all stories on this topic

Tysabri is back on US market
Unison.ie - Bray,Ireland
DRUGS company Elan and its partner, Biogen, said yesterday that their multiple sclerosis (MS) treatment Tysabri is now available again in the US. ...

Tysabri is back, but Elan is down -- time to buy
MSN Money - USA
... issue of Marketscope (Subscribers) (Free Trial), I said that Elan's (ELN, news, msgs) competitors would be pulling out all their guns to try to slow Tysabri. ...

Elan reintroduces Tysabri
Ireland Online - Dublin,Ireland
Athlone-headquartered pharmaceutical giant Elan has announced the reintroduction for sale in the US and Europe of multiple sclerosis drug Tysabri. ...

Biogen Idec, Elan announce availability of Tysabri
MarketWatch - USA
(BIIB) and Elan Corp. (ELN) announced the commercial availability of Tysabri for the treatment of relapsing forms of multiple sclerosis in the US. ...